<DOC>
	<DOCNO>NCT01795729</DOCNO>
	<brief_summary>The aim study compare optimal medical therapy alone versus percutaneous coronary intervention top medical therapy set heart transplant recipient coronary artery disease randomize trial.The primary endpoint assess 1 year composite death , myocardial infarction , need transitory permanent ventricular assist device implantation , myocardial revascularization , occurrence worsen heart failure , graft dysfunction and/or decrease leave ventricular ejection fraction least 25 % compare baseline . The hypothesis study superiority interventional management medical therapy alone prevent occurrence primary endpoint study .</brief_summary>
	<brief_title>Assessment Revascularization Versus Conservative Treatment Heart Transplant Patients Clinical Event Reduction</brief_title>
	<detailed_description>The hypothesis study superiority interventional management medical therapy alone prevent occurrence primary endpoint study assess 1 year randomization . Objectives : To demonstrate superiority interventional management top optimal medical therapy optimal medical therapy alone prevent occurrence primary endpoint study assess 1 year randomization Design : Multicenter , prospective randomize 1 :1 , open-label blind endpoint study Target population : Heart transplant recipient , age ≥18 year , without coronary artery disease-related symptom , angiographically significant coronary artery stenosis ( ≥50 % anatomically adequate revascularization coronary angioplasty stent implantation , contraindication dual antiplatelet therapy associate aspirin P2Y12 inhibitorfor duration 12 monthsand ni grade IA ACC/AHA indication revascularization Inclusion period : 12 month ( may extend base inclusion rythme ) Maximum duration participation patient : 13 month Total duration study : 37 month Primary endpoint : The composit death , myocardial infarction , retransplantation , implantation transitory definitve ventricular assist device , new worsen heart failure , graft failure and/or decrease leave ventricular ejection fraction least 25 % compare baseline.The occurrence event qualify primary endpoint assess Cox survival analysis stratify center.The primary endpoint assess 12 month randomization . Secondary endpoint : Any individual event define primary outcome 1 year Number patient include power calculation : 80 patient per group . A 1 year primary endpoint rate 30 % active 50 % inclusion period 24 month alpha=5 % warants 90 % power use cox model .</detailed_description>
	<criteria>Patients ≥ 18 year old Heart transplant recipient Stable clinical situation One several noncritical coronary stenosis ( ≥ 50 % et ≤ 75 % visually QCAassessed diameter stenosis ) consider adequate coronary stenting operator Left ventricular ejection fraction ≥ 40 % Informed consentement sign patient Acute coronary syndrome Instent restenosis Proof extensive myocardial ischemia ( ≥ 7/17 segment ASE model ) Coronary stenosis consider critical operator slow flow ACC/AHA Class IA indication revascularization : vessel disease leave ventricular dysfunction Left main stenosis Severe proximal LAD stenosis Contraindication dual antiplatelet therapy Decompensated heart failure time randomization Pregnant breastfeed woman Patients participate another clinical research within 30 day randomization life expectancy &lt; 1 Patients unable observe strict medical therapy followup within 1 year randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Heart transplant</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Allograft vascular disease</keyword>
	<keyword>Coronary stent</keyword>
	<keyword>Optimal medical therapy</keyword>
	<keyword>Prognosis</keyword>
</DOC>